{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T06:06:10Z","timestamp":1780553170334,"version":"3.54.1"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyper-inflammatory syndrome most commonly triggered by infection, autoimmune disease, or malignancy. Multiple myeloma (MM)-associated HLH is rare. We report a 70-year-old female who presented with HLH as the initial manifestation of MM. Following MM-directed therapy, both MM and HLH achieved remission; however, HLH relapsed with persistent Epstein\u2013Barr virus (EBV) viremia despite continued MM control. Anti-PD-1 monoclonal antibody therapy transiently suppressed EBV viremia, but HLH subsequently recurred. Repeat bone marrow examination revealed an unclassifiable aggressive large B-cell lymphoma. Because tissue biopsy was not feasible, lymphoma classification relied primarily on bone marrow findings, representing an important diagnostic limitation. Although EBER positivity was detected, this finding alone was insufficient to establish a direct pathogenic role of EBV in lymphoma development. Subsequent R-CHOP chemotherapy achieved temporary HLH control; however, severe chemotherapy-related myelosuppression and sepsis developed, and the patient ultimately died of multi-organ failure. This case highlights the challenges of developing lymphoid neoplasms in the setting of EBV-associated immune dysregulation, the diagnostic limitations of bone marrow-based lymphoma classification, the transient and limited efficacy of PD-1 blockade for EBV reactivation control, and the therapeutic difficulties encountered in this highly complex clinical setting.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1829220","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:42:03Z","timestamp":1780551723000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A diagnostic chameleon of EBV-associated immune dysregulation: HLH unmasking multiple myeloma with subsequent emergence of aggressive B-cell lymphoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Yang","family":"Dai","sequence":"first","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luocheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"West China Medical School, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xushu","family":"Zhong","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbing","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Institute of Hematology, and Center for High Altitude Medicine, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"State Key Laboratory of Biotherapy, Collaborative Innovation Center of Biotherapy, West China Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"National Facility for Translational Medicine (Sichuan), West China Hospital, Sichuan University","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-024-01621-x","article-title":"Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms","volume":"17","author":"Wu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.882589","article-title":"Epstein-Barr virus-positive lymphoma-associated hemophagocytic syndrome: a retrospective, single-center study of 51 patients","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(21)00366-5","article-title":"Malignancy-associated haemophagocytic lymphohistiocytosis","volume":"9","author":"Setiadi","year":"2022","journal-title":"Lancet Haematology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/bjh.17638","article-title":"Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes","volume":"196","author":"El-Mallawany","year":"2022","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2018.08.017","article-title":"Hemophagocytic lymphohistiocytosis in a patient with multiple myeloma","volume":"19","author":"Hsu","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02135-8","article-title":"Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis","volume":"38","author":"Knauft","year":"2024","journal-title":"Leukemia"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-381921","article-title":"EBV-associated T\/NK\u2013cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases","volume":"119","author":"Kimura","year":"2012","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003886","article-title":"Nivolumab treatment of relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults","volume":"135","author":"Liu","year":"2020","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.286264","article-title":"Prognostic impact of the immune microenvironment in multiple myeloma: a meta-analysis of current studies","volume":"110","author":"Susca","year":"2025","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2024.105697","article-title":"Epstein-Barr virus-associated B-cell lymphoproliferative disorders and lymphomas: diagnostic overlaps and defining features","volume":"156","author":"Volaric","year":"2025","journal-title":"Hum Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-7020-8165-1.00036-8","article-title":"Recognizing and managing secondary hemophagocytic lymphohistiocytosis in adults: a practical clinical guide","volume":"39","author":"Zoref-Lorenz","year":"2025","journal-title":"Hematology\/Oncology Clinics"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005041","article-title":"Checkmate for EBV-HLH","volume":"135","author":"El-Mallawany","year":"2020","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4198","article-title":"EBV-positive B-cell lymphomas and lymphoproliferative disorders: review from the perspective of immune escape and immunodeficiency","volume":"10","author":"Satou","year":"2021","journal-title":"Cancer Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829220\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T05:42:06Z","timestamp":1780551726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1829220\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":16,"alternative-id":["10.3389\/fimmu.2026.1829220"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1829220","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"article-number":"1829220"}}